Publix Q3 2026 Earnings Fall 9.9% as Comparable Sales Slip

Publix Super Markets Inc. reported net earnings of $1.1 billion for the third quarter ended Sept. 26, 2026, a 9.9% decline from $1.2 billion a year earlier, as sales rose just 1% to $15.5 billion and comparable store sales fell 0.6%. Earnings per share slipped to $0.33 from $0.37. Effective Nov. 1, 2026, the employee-owned grocer's internal stock price dropped from $19.60 to $18.70 per share, according to the company's quarterly filing.

Context — Why Publix's Q3 2026 Results Matter Now

The quarter marks a reversal for a grocer that had been growing sales, and the company tied the slowdown to two forces: the Medicare maximum fair price (MFP) change effective Jan. 1, 2026, which cut prices for 10 drugs, and economic conditions weighing on consumer spending. Both factors reduced sales and comparable store sales, the company said.

The MFP change is a direct policy hit to pharmacy revenue inside Publix stores. Drug price reductions lower the dollar value of each prescription filled, so even flat unit volumes translate into lower reported sales. The company did not disclose pharmacy's share of total revenue or quantify the MFP impact in dollars.

On the consumer side, Publix CEO Kevin Murphy said many customers are "feeling the effects of a challenging economy," and credited associates for the service they provide "during this time." That framing points to a shopper trading down or consolidating trips, a pattern grocery chains typically see before volume declines appear.

Publix's nine-month figures show the pressure is not a one-quarter event. Sales for the nine months ended Sept. 26, 2026 rose 1.4% to $47.4 billion from $46.8 billion, while comparable store sales fell 0.4% over the same period. Net earnings for the nine months slipped 1.5% to $3.5 billion.

The stock price cut is the clearest signal of how the board views the trend. Publix stock is not publicly traded and is available only to current associates and board members, so the internal valuation is set by the company rather than by market trading.

Data — What the Numbers Show

The headline comparison is straightforward: Q3 net earnings fell to $1.1 billion from $1.2 billion, and EPS dropped to $0.33 from $0.37. Nine-month EPS was unchanged at $1.10.

Stripping out unrealized gains on equity securities, the picture shifts. Excluding the fair value adjustment, Q3 net earnings would have been $908 million versus $980 million a year earlier, a 7.3% decline, with EPS of $0.29 versus $0.30. For the nine months, adjusted net earnings would have been $3.1 billion versus $3.2 billion, down 2.8%, with EPS of $0.97 versus $0.98.

Metric	Q3 2026	Q3 2025	Change
Sales	$15.5B	$15.4B	+1%
Comparable store sales	-0.6%	—	—
Net earnings	$1.1B	$1.2B	-9.9%
EPS	$0.33	$0.37	-10.8%
Adjusted net earnings	$908M	$980M	-7.3%
Adjusted EPS	$0.29	$0.30	-3.3%

The gap between reported and adjusted earnings is the unrealized gain on equity securities Publix holds: $212 million in Q3 2026 versus $272 million a year earlier, and $544 million versus $495 million over nine months. Because those gains flow through earnings, they flatter the reported figure.

The stock price change from $19.60 to $18.70 represents a 4.6% decline in the internal valuation. Publix operates 1,450 stores across eight states with roughly 260,000 associates.

Analysis — What It Means for Grocery and Pharmacy Exposure

The MFP mechanism is a structural headwind, not a one-off. Ten drugs had their prices cut effective Jan. 1, 2026, and the company said that change reduced sales. For any grocery chain with a pharmacy counter, the same arithmetic applies: lower drug prices mean lower revenue per script, even when foot traffic holds.

Publix is employee-owned and its shares are not listed, so there is no ticker for public markets to reprice. The read-through is indirect. National pharmacy chains and grocery peers with pharmacy operations face the same MFP mechanics, and the report's disclosure gives a concrete example of how the policy shows up in reported sales.

The counter-argument is that Publix's sales still grew 1% and 1.4% year over year, and nine-month net earnings fell only 1.5%. The reported declines are modest, and the adjusted figures show a smaller drop than the headline. A reader could argue the MFP drag is a level shift that laps in 2027, not a deteriorating trend.

The limitation is disclosure. Publix did not break out pharmacy revenue, did not quantify the MFP impact in dollars, and did not give comparable store sales for the prior-year quarter. Without those figures, the size of each driver cannot be separated.

Positioning is limited by structure. Because Publix stock trades only among associates and directors, there is no public flow to track. The relevant positioning question sits with investors in listed grocers and pharmacy operators who face the same MFP and consumer-spending backdrop.

Outlook — What to Watch Next

The next scheduled disclosure is Publix's fourth-quarter and full-year results, which the company typically releases in the following quarter. The company did not provide a date for that release in the report.

Two catalysts matter most. First, whether comparable store sales return to growth once the MFP change laps its first full year, which would show the drag was a level shift rather than a trend. Second, whether consumer spending stabilizes, given the company's own attribution of weakness to economic conditions.

On the internal stock, the level to watch is the new $18.70 price set effective Nov. 1, 2026, which replaced $19.60. Any further adjustment will be announced by the company, since the valuation is set internally rather than by trading.

Frequently Asked Questions

Why did Publix comparable store sales fall in Q3 2026?

Publix attributed the 0.6% decline in comparable store sales for the three months ended Sept. 26, 2026 primarily to the Medicare maximum fair price change effective Jan. 1, 2026, which cut prices for 10 drugs, and to economic conditions affecting consumer spending. The same two factors drove the 0.4% decline in comparable store sales over the nine-month period, the company said.

What is the Medicare maximum fair price change and how did it hit Publix?

The MFP change took effect Jan. 1, 2026 and reduced prices for 10 drugs. Publix said the change resulted in a decrease in sales, because lower drug prices mean less revenue per prescription filled. The company did not disclose pharmacy's share of total revenue or the dollar size of the impact, so the precise contribution cannot be isolated from the broader consumer-spending drag.

Why did Publix stock price drop to $18.70 per share?

Effective Nov. 1, 2026, Publix's internal stock price decreased from $19.60 to $18.70 per share, a 4.6% decline. Publix stock is not publicly traded and is available for sale only to current associates and members of the board of directors, so the price is set by the company rather than by open-market trading. The report did not state the methodology behind the adjustment.

Bottom Line

Publix's Q3 profit fell 9.9% and comparable sales turned negative as Medicare drug price cuts and softer consumer spending hit the employee-owned grocer.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.